Your browser doesn't support javascript.
loading
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.
Schindler, Hannah; Lusky, Fabienne; Daniello, Lea; Elshiaty, Mariam; Gaissmaier, Lena; Benesova, Karolina; Souto-Carneiro, Margarida; Angeles, Arlou Kristina; Janke, Florian; Eichhorn, Florian; Kazdal, Daniel; Schneider, Marc; Liersch, Stephan; Klemm, Sarah; Schnitzler, Paul; Stenzinger, Albrecht; Sültmann, Holger; Thomas, Michael; Christopoulos, Petros.
Afiliación
  • Schindler H; Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
  • Lusky F; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center of Lung Research (DZL), Heidelberg, Germany.
  • Daniello L; Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
  • Elshiaty M; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center of Lung Research (DZL), Heidelberg, Germany.
  • Gaissmaier L; Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
  • Benesova K; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center of Lung Research (DZL), Heidelberg, Germany.
  • Souto-Carneiro M; Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
  • Angeles AK; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center of Lung Research (DZL), Heidelberg, Germany.
  • Janke F; Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
  • Eichhorn F; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center of Lung Research (DZL), Heidelberg, Germany.
  • Kazdal D; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Schneider M; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Liersch S; Division of Cancer Genome Research (B063), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Klemm S; Division of Cancer Genome Research (B063), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Schnitzler P; Department of Thoracic Surgery, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
  • Stenzinger A; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center of Lung Research (DZL), Heidelberg, Germany.
  • Sültmann H; Department of Molecular Pathology Institute of Pathology Heidelberg, Heidelberg, Germany.
  • Thomas M; Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
  • Christopoulos P; Department of Pharmacy, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
Front Oncol ; 12: 1010660, 2022.
Article en En | MEDLINE | ID: mdl-36387148
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza